Skip to content

Author

Barbara T. Grünwald

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A064: Hub protein analysis identifies CAD as a mediator for drug resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor treatment options, emphasizing the need for novel therapeutic targets. Hub proteins have high connectivity (i.e., many interaction partners) and often act as central biological regulators. Here, we aimed to identify hub proteins with potential...

Foram Vyas, Virginie Defamie, Kelvin Yeung et al. · 0 citations
Sep 2026

Abstract B026: Multimodal spatial profiling uncovers cell state–associated receptor–ligand interactions in pancreatic ductal adenocarcinoma

Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...

Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al. · 0 citations
Sep 2026

Abstract PR007: Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations

The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.

Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al. · 0 citations
Sep 2026

Abstract A039: Epigenetic regulation of cellular heterogeneity and the tumor-immune landscape in pancreatic cancer

Cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for disease prognosis and limits the effectiveness of therapeutic strategies implemented in recent multicenter subtype-based clinical trials worldwide. A hallmark of PDAC is extensive intratumoral heterogeneity, which is la...

Xue-Yan Wu, L. Klein, M. Tu et al. · 0 citations
Sep 2026

Abstract A027: Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.

M. Dorsch, Felix E. G. Beaudry, A. Baginska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.